Jupiter Neurosciences, INC S-1 registration statements

Jupiter Neurosciences, Inc. has filed a registration statement for the resale of up to 16,000,000 shares of common stock by YA II PN, LTD (Yorkville) pursuant to an existing Standby Equity Purchase Agreement.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, has entered a $20 million standby equity purchase agreement with Yorkville to fund its Parkinson's trial and Nugevia brand launch, despite significant and increasing net losses and a going concern warning.

Jupiter Neurosciences files an amendment to its Form S-1 registration statement to include the consent of Assurance Dimensions and update the exhibit index.

Jupiter Neurosciences amends its S-1 registration statement, highlighting its focus on Parkinson's disease treatment with JOTROL and potential expansion in the South-East Asian market.

Jupiter Neurosciences aims to raise capital through an IPO to fund the development of its Parkinson's drug, JOTROL, and expand its business operations in Southeast Asia.

Jupiter Neurosciences is seeking to raise capital through an IPO to advance its JOTROL drug, particularly for Parkinson's disease, and expand into the South-East Asian market.

Jupiter Neurosciences introduces a new equity incentive plan to attract and retain key personnel and promote company success.